Osimertinib

Org: Klinik für Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin, Germany, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation, Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy,

Clinical trial

A Single-Center, Prospective, Single-Arm, Observational Study Evaluating the Efficacy and Safety of Osimertinib Combined With Etoposide as First-Line Treatment in Patients With Osimertinib-Resistant or -Insensitive, Advanced EGFR-Mutant Non-Small Cell Lung Cancer

Status: Not yet recruiting, Estimated PCD: 2029-06-01

Clinical trial

A Prospective, Pilot Study of First-line Osimertinib With or Without Savolitinib in de Novo MET Positive, EGFR-mutant NSCLCs (FLOWERS)

Status: Active (not recruiting), Estimated PCD: 2024-04-01

Abstract

Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.

Org: Princess Margaret Cancer Centre, Wakayama Medical University, Wakayama, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Jilin Cancer Hospital, Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research,

Abstract

Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.

Org: Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Medical Oncology, Regional University Hospital of Málaga, Málaga, Spain, Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France,

Clinical trial

A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) as First-Line Therapy in Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting, Estimated PCD: 2024-12-31

Abstract

OSIRAM-1/TORG1833: Overall survival results of a randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer.

Org: Kurume University Hospital, Teikyo University School of Medicine, National Hospital Organization Yokohama Medical Center,

Abstract

Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations.

Org: Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center,

Abstract

Young adults (YA) with non-small cell lung cancer (NSCLC): Snapshot of the oncogenic drivers and immune landscapes.

Org: The James, The Ohio State University Comprehensive Cancer Center,

Abstract

Tyrosine kinase inhibitors with and without upfront CNS radiation for brain metastases in oncogene-driven non-small cell lung cancer (TURBO-NSCLC).

Org: The James Cancer Hospital, Ohio State University Wexner Medical Center, University of Colorado Denver, Anschutz Medical Campus,

Abstract

Assessing quality of care in early stage resected stage non-small cell lung cancer (NSCLC): An evaluation of epidermal growth factor receptor (EGFR) testing and adjuvant (adj) therapy (tx).

Org: Genesis Cancer Center,

Abstract

A phase I/Ib study of the aurora kinase A inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer.

Org: University of California, San Francisco, San Francisco, CA,

Abstract

A randomized phase II trial of 8 months of afatinib switching to osimertinib (A) versus osimertinib alone (B) as first-line treatment in advanced NSCLC patients with common EGFR mutation: YAMATO study (TORG1939/WJOG12919L).

Org: Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan, Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan, Department of Respiratory Medicine, Japanese Red Cross Ise Hospital, Ise, Japan, Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan,

Abstract

A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).

Org: Kitasato Univeristy Hospital, Sagamihara-Shi, Japan, Toho University Omori Medical Center, Tokyo, Japan, Division of Respirology Neurology and Rheumatology Department of Internal Medicine, Kurume University Hospital, Kurume, Japan, Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan, Tochigi Cancer Center, Utsunomiya, Japan,

Abstract

Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).

Org: JSInnoPharm, JS InnoPharm (Shanghai) Ltd,

Abstract

Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.

Org: University of Malaya Medical Centre, Hospital Umum Sarawak, Hospital Tengku Ampuan Afzan, First Affiliated Hospital of Army Medical University, Huizhou Municipal Central Hospital of Guangdong Province,

Abstract

TOP: A phase III, multicentre, randomized controlled study comparing osimertinib in combination with carboplatin and pemetrexed to osimertinib monotherapy for untreated patients with advanced non-squamous (Non-sq) non-small cell lung cancer (NSCLC) with concurrent EGFR and TP53 mutations.

Org: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China, The First People's Hospital of Foshan, Foshan, China, Department of Respiratory Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China, Central Hospital of Guangdong Provincial Nongken, Zhanjiang, China, Henan Cancer Hospital, Zhengzhou, China, Taizhou First People's Hospital, Taizhou, China, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, The First People's Hospital of Changzhou, Changzhou, China, Shengli Oilfield Central Hospital, Dongying, China, Taizhou Central Hospital, Taizhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China,

Abstract

A phase II, open-label, single-arm, multicenter, efficacy and safety study of 80 mg osimertinib in patients with leptomeningeal metastases (LM) associated with epidermal growth factor receptor (EGFR) mutation–positive non-small cell lung cancer (NSCLC): BLOSSOM.

Org: Section of Hematology-Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, South Korea, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, AstraZeneca, Cambridge, United Kingdom, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea, National Cancer Center, Goyang, South Korea, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea, Keimyung University, Daegu, South Korea,

Abstract

Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.

Org: Federal University of Amazonas - UFAM, Federal University of Pará - UFPA, Catholic University of Pelotas, University Hospital HUG,

Abstract

Immune infiltrate characterization and differential gene expression by RNA-sequencing analysis in patients with oncogene-addicted NSCLC with early progression under targeted therapy.

Org: Genomic Platform and Biobank, AMMICa UAR3655/US23, Gustave Roussy, Cancer Campus,

Abstract

Org: West Virginia University Camden Clark Medical Center, Morgantown, WVU Camden Clark Medical Center,

Abstract

Evaluating generalizability of landmark randomized controlled trials in common metastatic cancers using machine learning-based emulated trials.

Org: Navajo Indian Health Service,

Abstract

Cutaneous adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer: A meta-analysis of phase 3 randomized controlled trials.

Org: Mount Sinai Beth Israel, Mount Sinai Hospital-Breast Medical Oncology, Kyoto University Hospital, Center for Thoracic Oncology, Tisch Cancer Institute,

Abstract

Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC.

Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Center for Molecular Oncology,

Abstract

Timing of EGFR or ALK inhibitor initiation and survival among patients with advanced NSCLC.

Org: Department of Thoracic Oncology, Kanagawa Cancer Center, H. Lee Moffitt Cancer Center and Research Institute,

Abstract

A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease.

Org: Stanford University Department of Radiation Oncology,

Abstract

Real-world outcomes of osimertinib in Peruvian patients with advanced NSCLC with EGFR T790M-positive: A multi-institutional experience.

Org: Hospital Centro Médico Naval, Hospital Nacional PNP, Hospital Central FAP, Clinica Good Hope,

Abstract

Cost analysis of targeted and immunotherapies in operable esophageal and non-small cell lung cancers.

Org: Division of General Thoracic Surgery, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery,

Abstract

Evaluating progression-free survival of EGFR exon 20ins in patients with advanced non-small lung cancer receiving EGFR inhibitors: A real-world data study.

Org: BioSpark AI Technologies,

Abstract

Validation of article analysis by ChatGPT: Using a cohort of patients with EGFR mutation-positive non-small cell lung cancer treated with first-line osimertinib.

Org: Sunto-Gun, Sunto-Gun Nagaizumi-Cho, 411-8777,

Abstract

Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.

Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, National Cancer Centre Singapore, Department of Clinical Oncology, Queen Elizabeth Hospital, The Chinese University of Hong Kong, Prince of Wales Hospital,

Abstract

Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutant NSCLC with brain metastases: A dynamic ctDNA-guided study.

Org: Beijing Fengtai District,

Abstract

Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).

Org: Fred Hutchinson Cancer Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,

Abstract

Exploring the significance of MET overexpression by gene expression profiling versus immunohistochemistry in an EGFR-mutant lung cancer cohort.

Org: Medanta Medicity, Gleneagles BGS Hospital, Sahyadri Hospital, HCA Healthcare UK, Metro Hospital,

Clinical trial

A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2025-12-27

Clinical trial

A Multicentre Single-arm Phase II Trial Assessing the Safety and Efficacy of First-line Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2026-03-01

Clinical trial

A Phase I Study of Osimertinib, Cetuximab, and Tucatinib in Advanced EGFR-Mutant NSCLC With Acquired Resistance to Osimertinib

Status: Not yet recruiting, Estimated PCD: 2025-01-01

Clinical trial

Uncommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-life Practice in First Line Setting

Status: , Estimated PCD: 2024-09-01

Clinical trial

An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC

Status: Active (not recruiting), Estimated PCD: 2024-05-01

Clinical trial

A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases

Status: Active (not recruiting), Estimated PCD: 2024-07-01

Clinical trial

A Phase II, Multi-centre Study, to Evaluate the Efficacy and Safety of Osimertinib Treatment for Patients With EGFR-mutated Non-small Cell Lung Cancer (NSCLC) With Brain or Leptomeningeal Metastases

Status: Active (not recruiting), Estimated PCD: 2023-03-15

Clinical trial

MATCH Treatment Subprotocol E: Osimertinib (AZD9291) in Patients With Tumors Having EGFR T790M Mutations or Rare Activating Mutations of EGFR

Status: Active (not recruiting), Estimated PCD: 2024-05-26

Clinical trial

A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Status: Completed, Estimated PCD: 2024-04-30

Clinical trial

Phase 1 Trial of Osimertinib With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From EGFR Positive Non-Small-Cell Lung Cancer (NSCLC)

Status: Completed, Estimated PCD: 2022-04-01

Clinical trial

A Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination With Ipilimumab in Patients With EGFR Mutated Non-Small-Cell Lung Cancer Tumors

Status: Active (not recruiting), Estimated PCD: 2025-04-30

Clinical trial

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy (LCT) for Patients With EGFR-Mutant Metastatic NSCLC (NORTHSTAR)

Status: Active (not recruiting), Estimated PCD: 2025-06-01

Clinical trial

Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Neoadjuvant Osimertinib Plus Chemotherapy for EGFR-mutant Stage III N2 Non-squamous Non-small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2023-09-01

Clinical trial

An Open-label, Single-arm, Investigator-initiated Phase I Clinical Study Evaluating BPI-1178 Capsules in Combination With Osimertinib Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With EGFR Mutations

Status: Not yet recruiting, Estimated PCD: 2025-04-01

Clinical trial

A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2023-01-31

Clinical trial

National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2024-09-01

Clinical trial

Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined With Osimertinib in Patients With Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).

Status: Recruiting, Estimated PCD: 2026-04-01

Clinical trial

Phase 1 Study of Combination Dacomitinib and Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers

Status: Active (not recruiting), Estimated PCD: 2025-01-01

Clinical trial

A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor

Status: Active (not recruiting), Estimated PCD: 2024-07-30

Clinical trial

Whole Genomic Landscape of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Treated With First-Line Osimertinib (WARRIOR)

Status: Active (not recruiting), Estimated PCD: 2025-09-30

Clinical trial

Neo-Bio-ADAURA: A Single Arm, Multi-Centre Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib.

Status: Not yet recruiting, Estimated PCD: 2029-01-01

Clinical trial

A Phase II Trial of Osimertinib and Abemaciclib With a Focus on Non-Small Cell Lung Cancer Patients With EGFR Activating Mutations With Osimertinib Resistance

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) - A Multicentric Phase II Study in Patients With TKI-resistant EGFR-mutated Lung Cancer Exhibiting Early Metabolic Response to Osimertinib

Status: Completed, Estimated PCD: 2021-12-31

Clinical trial

Creating Metabolic Vulnerabilities in Patients With EGFR Activated Recurrent Glioblastoma by Inhibiting EGFR With Osimertinib

Status: Active (not recruiting), Estimated PCD: 2024-10-01

Clinical trial

Phase 1 Study of Combination Osimertinib, Platinum, Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers With Concurrent RB1 and TP53 Alterations

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progressionon Osimertinib.

Status: Completed, Estimated PCD: 2023-07-07

Clinical trial

Phase II Trial of Osimertinib in Combination With Stereotactic Ablative Radiation (SABR) in EGFR Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Status: Active (not recruiting), Estimated PCD: 2024-09-30

Clinical trial

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Status: Recruiting, Estimated PCD: 2026-12-24

Clinical trial

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line Setting

Status: Active (not recruiting), Estimated PCD: 2024-06-30

Clinical trial

A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Following Complete Tumour Resection

Status: Recruiting, Estimated PCD: 2027-08-02

Clinical trial

A Phase 1 Open-Label Study of HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

A Phase II Study Evaluating Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated Non-small Cell Lung Cancer (NSCLC)

Status: Not yet recruiting, Estimated PCD: 2026-03-01

Clinical trial

A Phase II Study of Pembrolizumab Plus Platinum and Pemetrexed as First Line Therapy in Advanced Non-squamous Non-small Cell Lung Cancer Patients With EGFR Exon 21 Point Mutation and Programmed Cell Death Ligand 1 Expression

Status: Not yet recruiting, Estimated PCD: 2027-11-30

Clinical trial

Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Status: Recruiting, Estimated PCD: 2023-11-01

Clinical trial

Osimertinib as Neoadjuvant Therapy in Patients With Resectable Stage II-IIIB EGFR-mutated Lung Squamous Cell Carcinoma: A Single-centre, Single-arm, Phase 2 Trial

Status: Recruiting, Estimated PCD: 2025-10-31

Clinical trial

A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).

Status: Recruiting, Estimated PCD: 2025-06-26

Clinical trial

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

Status: Recruiting, Estimated PCD: 2024-02-28

Clinical trial

AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies

Status: Active (not recruiting), Estimated PCD: 2023-06-01

Clinical trial

A Prospective, National, Multi-centric, Non-interventional Study of First Line Osimertinib in Chinese Patients With Locally Advanced/Metastatic，EGFR Mutation-positive NSCLC in Real World Setting

Status: Active (not recruiting), Estimated PCD: 2022-04-26

Clinical trial

A Randomised Non-comparative, Phase II Study Investigating the Best Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Sequence in Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) Harboring EGFR Mutations

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2025-04-01

Clinical trial

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Status: Active (not recruiting), Estimated PCD: 2024-04-30

Clinical trial

A Phase Ib/II Trial to Evaluate Safety, Tolerability and Efficacy of Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Clinical trial

A Phase 1 Trial of MLN0128 (TAK-228) in Combination With Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor

Status: Active (not recruiting), Estimated PCD: 2024-06-29

Clinical trial

A Ph1b Study of Osimertinib + Alisertib or Sapanisertib for Osimertinib-Resistant EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) (Crossover Study)

Status: Completed, Estimated PCD: 2023-07-27

Clinical trial

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

A Phase Ib Study of Osimertinib (AZD9291) and Telaglenastat (CB-839) HCl in Patients With EGFR Mutant Non-Small Cell Lung Cancer

Status: Active (not recruiting), Estimated PCD: 2025-06-01

Clinical trial

UCLA L-08: A Phase Ib/II Study of Combined HER Inhibition Adding Necitumumab and Trastuzumab to Osimertinib in Patients With Refractory EGFR-Mutated Lung Cancer

Status: Recruiting, Estimated PCD: 2024-12-02

Clinical trial

A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Clinical trial

Phase I/II Study Exploring the Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Status: Recruiting, Estimated PCD: 2027-09-30

Abstract

Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

Org: Medical Oncology, Yale School of Medicine, Yale Cancer Center, Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan,

Abstract

Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.

Org: National Taiwan University Hospital and National Taiwan University Cancer Center, Seoul National University Bundang Hospital, Istituto Europeo di Oncologia, Osaka International Cancer Institute, Osaka, Japan, Peking Union Medical College Hospital,

Abstract

Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.

Org: Gustave Roussy Cancer Center, University of Pennsylvania, National Cancer Center Hospital East, Kashiwa, Japan, Seoul National University Bundang Hospital, Yonsei University College of Medicine,

Abstract

Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer.

Org: University of California, San Francisco, The University of California, San Francisco, University of Colorado Comprehensive Cancer Center, UC Davis Comprehensive Cancer Center, Dana-Farber Cancer Institute,

Abstract

EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.

Org: Perelman Center for Advanced Medicine, Philadelphia, PA, Lifespan Cancer Institute, Providence, RI, Virginia Cancer Specialists, Fairfax, VA, Peter MacCallum Cancer Centre, Melbourne, Australia, MD Anderson Cancer Center, Houston, TX,

Abstract

Phase 3 study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG3515).

Org: AstraZeneca,

Abstract

Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib.

Org: Division of Medical Oncology, National Cancer Centre, Singapore, Singapore, Seoul National University Cancer Research Institute, Seoul, Republic of Korea,

Abstract

Elucidating the genomic and transcriptomic landscape of L858R vs ex19del EGFR-mutated NSCLC.

Org: National Cancer Centre Singapore, Genome Institute of Singapore, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center, National Heart Centre Singapore,

Abstract

First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of WSD0922-Fu: Initial report from dose escalation cohort.

Org: Mayo Clinic, Rochester, MN, Jacksonville, FL, Phoenix, AZ, Wayshine Biopharm,

Abstract

Differential expression analysis of circRUNX1 in patients with early resected EGFR-mutant NSCLC.

Org: Pangaea Oncology, Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, Surgical Oncology, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Institute of Biomedical & Health Sciences, Hiroshima University, University of Granada,

Abstract

A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.

Org: Department of Hematology and Clinical Oncology, Shinshu University School of Medicine, Matsumoto-Shi, Japan, Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Mibu, Japan, Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan,

Abstract

Clinical and genomic landscape of EGFR-mutant lung cancers (LCs) with squamous and adenosquamous differentiation.

Org: Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Memorial Sloan Kettering Cancer Center,

Abstract

EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).

Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Brigham and Women's Hospital/Massachusetts General Hospital, Princess Margaret Cancer Centre, Stanford Cancer Institute, Mayo Clinic,

Abstract

The safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: Preclinical mouse model and phase I/IIa clinical study.

Org: C&SR Inc., NKMAX Co., Ltd., NKGen Biotech Inc.,

Abstract

First report of ELUCIDATOR study: A prospective observational multicenter study on resistance mechanisms in patients with early disease progression during osimertinib.

Org: National Hospital Organization Himeji Medical Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Center for Biomedical Sciences, Wakayama Medical University, Wakayama, Japan, Wakayama Medical University, Wakayama, Japan, National Hospital Organization Asahikawa Medical Center,

Abstract

Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.

Org: National Cancer Center Hospital East, Kashiwa, Japan, Graduate School of Medicine, The University of Tokyo, Nippon Medical School Hospital, Yamaguchi University Graduate School of Medicine, Tokyo Metropolitan Komagome Hospital,

Abstract

Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC).

Org: Genentech, Princess Margaret Cancer Centre, Norris Comprehensive Cancer Center, Laura and Isaac Perlmutter Cancer Center, Lombardi Comprehensive Cancer Center,

Abstract

Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).

Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Nashville, TN, EQRx, Cambridge, MA,

Abstract

Prevention of amivantamab infusion related reactions with extended pre-infusion day oral steroid therapy.

Org: Icon Cancer Centre, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center,

Abstract

Predictive value of co-existing genetic alterations and tumor mutation burden for patients with completely resected non-small cell lung cancer harboring EGFR mutation: Biomarker analysis of phase III IMPACT study.

Org: Kanagawa Cardiovascular and Respiratory Center, National Cancer Center Hospital East, Kashiwa, Japan, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Department of Data Sciences, Internal Medicine III, Wakayama Medical University,

Abstract

Safety and efficacy of stereotactic body radiotherapy (SBRT) to oligoresidual sites combine with osimertinib in stage IV EGFR mutant NSCLC patients: A prospective pilot study.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Fujian Medical University Union Hospital, Department of PET/CT Center, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Nosocomial Infection Control Branch, Fujian Medical University Union Hospital, Fuzhou, Fujian, China,

Abstract

Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer.

Org: Yale School of Medicine, New Haven, CT, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Plantsville, CT, Yale University,

Abstract

Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients.

Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Research Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, University of Washington School of Medicine,

Abstract

Artificial neural network model analysis in T790M detection after failure of first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.

Org: Maria Sklodowska-Curie National Research Institute of Oncology, Division of Biostatistics and Neural Networks, Medical University of Gdańsk, Lung and Thoracic Cancer Department, Maria Sklodowska-Curie National Research Institute of Oncology,

Abstract

AX-0085, a novel AXL kinase inhibitor, and effects on osimertinib-resistance in non–small-cell lung cancer.

Org: Axceso Biopharma Co., Ltd., College of Medicine, Hanyang University, Department of Life Science, Ewha Research Center for Systems Biology, Ewha Womans University,

Abstract

Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).

Org: Schulich School of Medicine and Dentistry, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, London Regional Cancer Program, University Health Network,

Abstract

Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.

Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine,

Abstract

UCLA l-08: A phase ib/II study of combined HER inhibition adding necitumumab and trastuzumab to osimertinib in patients with refractory EGFR-mutated lung cancer.

Org: David Geffen School of Medicine at University of California Los Angeles, Weizmann Institute of Science,

Abstract

Liquid and tissue profiling of targetable co-mutations with KRAS in non-small cell lung cancer.

Org: Fortis Cancer Institute, Rajiv Gandhi Cancer Institute and Research Centre, Tata Memorial Centre, Datar Cancer Genetics, Datar Genetics Limited,

Abstract

Cancer therapy-associated thrombosis: A patient- reported outcomes (PROs) analysis.

Org: Care Across,

Abstract

A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).

Org: National Cancer Center Hospital East, Kashiwa, Japan, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Osaka International Cancer Institute, Osaka, Japan, Kanagawa Cancer Center, Itami City Hospital,

Abstract

Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.

Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Columbia University Irving Medical Center, New York, NY, USA, New York, NY,

Abstract

A multicenter study of central nervous system (CNS) metastasis in EGFR-mutated advanced non–small-cell lung cancer in Thailand: CNS progression-free survival analysis.

Org: Chulabhorn Oncology Medical Center, Chulabhorn Hospital, Chulabhorn Royal Academy, Surin Hospital, Police General Hospital,

Abstract

Concurrent EGFR wild-type tongue squamous cell carcinoma and EGFR-mutant lung adenocarcinoma and response to osimertinib.

Org: Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha, China, Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China, Hunan Academy of Traditional Chinese Medicine Affiliated Hospital, Changsha, China, Department of Pathology, Xiangya Hospital, Central South University, Changsha, China, Pharmacy, Hunan University of Chinese Medicine, Changsha, China,

Abstract

Genomic profiling of cerebrospinal fluid ctDNA to characterize molecular features and monitor intracranial responses of patients with osimertinib-resistant non-small cell lung cancer with leptomeningeal metastases.

Org: 3D Medicines Inc.,

Abstract

Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University Hospital of Cologne, China Medical University Hospital, Bhaktivedanta Hospital And Research Centre and School of Consciouness,

Abstract

Clinical efficacy analysis of furmonertinib and structural insights into sensitivity to diverse TKIs for NSCLC with EGFR exon 20 insertion.

Org: Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhoukou Central Hospital, Zhumadian Central Hospital,

Abstract

ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D).

Org: Valkyrie Clinical Trials, Inc, Rocky Mountain Cancer Centers, Millennium Oncology, Virginia Cancer Specialists, Genprex,

Abstract

Efficacy and safety study of osimertinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation.

Org: Hospital Juan Ramón Jiménez, Hospital Juan Ramón Jimenez,

Abstract

Predictors of benefit to radiation for oligoprogressive disease in EGFR-mutant metastatic non-small cell lung cancer patients treated with osimertinib.

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Retreatment with EGFR inhibitor in non-small cell lung cancer patients previously exposed to EGFR-TKI: A systematic review and meta-analysis.

Org: Catholic University of Pelotas, Princess Margaret Hospital, Universidade de Brasília, Centro de Oncologia do Parana, Universidade Estadual do Centro Oeste - UNICENTRO, Guarapuava, Brazil,

Abstract

High-throughput drug screening (HTDS) of patient-derived tumor organoids (PTDO) from advanced gastrointestinal malignancies: Response and identification of novel therapeutic options.

Org: Weill Cornell Medical College University, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, NewYork-Presbyterian/Weill Cornell Medical Center, Joan and Sanford I Weill Medical College of Cornell University, NYP/Columbia,

Abstract

Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.

Org: Memorial Sloan Kettering Cancer Center, Department of Pathology, Aberdeen University Medical School & Aberdeen Royal Infirmary, Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Department of Thoracic Oncology, Peking University Cancer Hospital, IRCCS Humanitas Research Hospital, Rozzano, Italy,

Abstract

Differential efficacy of tyrosine kinase inhibitors (TKIs) according to the types of EGFR mutations and agents in non-small cell lung cancer (NSCLC): A real-world study.

Org: Ajou University School of Medicine, Department of Hematology-Oncology, Ajou University Hospital,

Abstract

Prognostic impact of baseline circulating extracellular vesicles (BCEVs) in the setting of patients with advanced non-small cell lung cancer (ANSCLC) eligible for first line treatment with osimertinib.

Org: Department of Surgical Oncological and Oral Sciences, University of Palermo, Dept of Surgery-Oncology and Oral Sciences, Institute of Translational Pharmacology (IFT), National Research Council (CNR) of Italy,

Abstract

Clinical analysis of the presence of comutations in patients with EGFR-mutated NSCLC.

Org: University Hospital Fundación Jiménez Díaz, Hospital Universitario Fundación Jiménez Díaz, Fundacion Jimenez Diaz University Hospital, Fundación Jiménez Díaz, University Hospital Fundacion Jimenez Diaz,

Abstract

Treatment adherence and clinical outcomes of osimertinib (Osi) among ethnic-minority patients (pts) with EGFR-mutated NSCLC.

Org: Montefiore-Einstein Cancer Center, The Bronx, NY, Nykode Therapeutics, Albert Einstein College of Medicine, Bronx, NY,

Abstract

Clinical outcomes and genomic landscape of patients (pts) with EGFR-mutant lung cancer (EGFR+ LC) with central nervous system (CNS) metastases (mets).

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Patients harboring uncommon EGFR exon 19delins variants of advanced non-small-cell lung cancer and response to osimertinib: A multi-center retrospective study.

Org: The Second Affiliated Hospital Of Nanchang University, Jiangxi Cancer Hospital, Jiujiang Cancer Hospital, Jiangxi Key Laboratory of Clinical Translational Cancer Research,

Abstract

Prevalence of EGFR and PDL1 testing in a population-based lung cancer surgical resection cohort from 2018-2022.

Org: University of Memphis, School of Public Health, Fudan University, Memphis, TN, Baptist Cancer Center, Memphis, TN, Multidisciplinary Thoracic Oncology Department,

Abstract

Treatment outcomes in patients (pts) with advanced/metastatic non‑small cell lung cancer (NSCLC) harboring MET amplification as a secondary oncogenic driver.

Org: West Cancer Center & Research Institute, Merck, Global Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany,

Abstract

Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutated NSCLC with brain metastasis instructed by dynamic monitoring circulating tumor DNA of paired cerebrospinal fluid and plasma.

Org: Beijing Tiantan Hospital, Beijing Tian Tan Hospital, Capital Medical University, Capital Medical University,

Abstract

Preliminary results from the Female Asian Nonsmoker Screening Study (FANSS).

Org: NYU Langone Perlmutter Cancer Center, NYU Perlmutter Cancer Center, Massachusetts General Hospital, Chao Family Comp Cancer Ctr, NYU Grossman School of Medicine, Department of Population Health,

Abstract

An individual patient-level meta-analysis of non–small-cell lung cancer leptomeningeal metastases treated with epidermal growth factor receptor inhibitors.

Org: McGill University Health Center, The Second Affiliated Hospital Of Nanchang University, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Mayo Clinic, Memorial Sloan Kettering Cancer Center,

Product

AZD9291 + Continuous Selumetinib

Product

gefitinib or osimertinib, followed by cisplatin and pemetrexed, then gefitinib or osimertinib

Product

osimertinib + radiation therapy

Product

EGFR tyrosine kinase inhibitors

Product

Osimertinib + Bevacizumab

Product

osimertinib + anlotinib